[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349925-105":59,"doc-detail-349925-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","enhancement-of-gemcitabine-toxicity-and-specificity-through-pi3kaktnrf2-pathway-inhibition-in-pancreatic-cancer","Enhancement of gemcitabine toxicity and specificity through PI3K/Akt/Nrf2 pathway inhibition in pancreatic cancer","","Enhancement of gemcitabine performance in pancreatic ductal adenocarcinoma is investigated by targeting survival and chemoresistance signaling centered on PI3K/Akt/Nrf2. The study selects a fragment-based drug sensitiser, BD B10, using structural similarity screening, then evaluates its effects alone and in combination with gemcitabine in PDAC and noncancerous pancreatic cell models. Cell viability, apoptosis, migration, and pathway activity are quantified using microscopy, flow cytometry, RT-qPCR, Western blot, and RNA sequencing with pathway analysis. Combination therapy increases apoptosis, reduces migration, impairs PI3K/Akt/Nrf2, STAT3, and Wnt/β-catenin signaling, and improves the therapeutic index without adverse effects on noncancerous growth.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/enhancement-of-gemcitabine-toxicity-and-specificity-through-pi3kaktnrf2-pathway-inhibition-in-pancreatic-cancer/349925/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/enhancement-of-gemcitabine-toxicity-and-specificity-through-pi3kaktnrf2-pathway-inhibition-in-pancreatic-cancer/349925.png","ImageObject",300,407,{"name":92,"@type":93},"Rowan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-12","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address in pancreatic cancer treatment?","Question",{"text":112,"@type":113},"It targets limited gemcitabine efficacy caused by chemoresistance mechanisms, including pathways involving PI3K/Akt/Nrf2 and related drug efflux and survival signaling in PDAC.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was BD B10 selected in the study?",{"text":117,"@type":113},"BD B10 was chosen from a fragment library using Tanimoto coefficient similarity to trigonelline and tryptamine before testing in cell models.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key findings of combining BD B10 with gemcitabine?",{"text":121,"@type":113},"The combination reduced the gemcitabine dose requirement, enhanced drug efficacy, increased apoptosis, reduced migration, and impeded PI3K/Akt/Nrf2 as well as STAT3 and Wnt/β-catenin signaling.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349925,1790125964,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","TYPE Original Research PUBLISHED 16 February 2026 DOI 10.3389/fphar.2026.1724989  \nOPEN ACCESS  \nEDITED BY  \nAmin Gasmi,  \nFrancophone Society of Nutritherapy and Applied Nutrigenetics, France  \nREVIEWED BY  \nMohammad Ahsan Saad,  \nWellman Center for Photomedicine, Massachusetts General Hospital, United States Hnin Ei Ei Khine,  \nMahidol University, Thailand  \n*CORRESPONDENCE  \nPhilip J. R. Day,  \n [philip.j.day@manchester.ac.uk](philip.j.day@manchester.ac.uk)  \nRECEIVED 14 October 2025  \nREVISED 14 December 2025  \nACCEPTED 05 January 2026  \nPUBLISHED 16 February 2026  \nCITATION  \nChen Y-S, O’Hagan S and Day PJR (2026) Enhancement of gemcitabine toxicity and specificity through PI3K/Akt/Nrf2 pathway inhibition in pancreatic cancer.  \nFront. Pharmacol. 17:1724989 .  \ndoi: 10.3389/fphar.2026.1724989  \nCOPYRIGHT  \n© 2026 Chen, O’Hagan and Day. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nEnhancement of gemcitabine toxicity and specificity through PI3K/Akt/Nrf2 pathway inhibition in pancreatic cancer  \nYu-Shan Chen 1, Stephen O’Hagan 2 and Philip J. R. Day 1,3*  \n1Division of Evolution, Infection and Genomic Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, 2School of Chemistry, Department of Chemistry, Dover Street Building, The University of Manchester, Manchester, United Kingdom, 3Department of Medicine, University of Cape Town, Cape Town, South Africa  \nIntroduction: Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy associated with rapid metastasis and chemoresistance driven by PI3K/Akt/Nrf2 signalling and drug efflux transporters. The lack of symptoms and early diagnosis are clinically challenging, and the development of new medications is limited. Therefore, a new strategy to enhance gemcitabine efficacy without increasing systemic toxicity has been demonstrated.  \nMethods: The fragment-based drug sensitiser BD B10 was selected from a Maybridge fragment library using the Tanimoto coefficient to identify structural similarity to trigonelline and tryptamine. PDAC cell lines and noncancerous pancreatic cells were reated with gemcitabine, BD B10, or their combination. Cell viability, apoptosis, migration, and signalling pathways were analysed using microscopy, flow cytometry, RT-qPCR, Western blot, and RNA Seq with pathway analysis.  \nResults: Applying BD B10 in PDAC cell lines reduced the dose requirement of gemcitabine by 10%, with no adverse effects on growth of non-cancerous pancreatic cell lines, enhancing drug efficacy by 12%, with a otential marked gain in therapeutic index. Additionally, combination treatment enhanced apoptosis, reduced migration, and impeding PI3K/Akt/Nrf2, STAT3, and Wnt/β -catenin signalling regulation.  \nDiscussion: BD B10 was identified as a non-toxic drug sensitiser that enhanced gemcitabine efficacy in PDAC cells and improved the therapeutic index by inhibiting key survival and resistance pathways. Specific roles for BD B10 in PDAC were identified and further testing may prove drug sensitisers have amore general application to enhance drug therapies.  \nKEYWORDS  \nbinary drug, chemoresistance, drug sensitiser, enhanced drug efficacy, PDAC, PI3K/Akt/ Nrf2 pathway  \nIntroduction  \nPancreatic cancer is ranked the 3rd leading cause of cancer-related mortality in the United States and 7th worldwide, with approximately 90% of cases being pancreatic ductaladenocarcinoma (PDAC) (Stoffel et al., 2023; Partyka et al., 2023) . Since PDAC lacks early symptoms and has a late diagnosis, PDAC is predicted to surpass colorectal cancer as the se","cbCaioMouWpfBeth","https://ap.wps.com/l/cbCaioMouWpfBeth","pdf",5751226,18,"English","# Introduction\n# Methods\n# Results\n# Discussion","[{\"question\":\"What problem does the study address in pancreatic cancer treatment?\",\"answer\":\"It targets limited gemcitabine efficacy caused by chemoresistance mechanisms, including pathways involving PI3K/Akt/Nrf2 and related drug efflux and survival signaling in PDAC.\"},{\"question\":\"How was BD B10 selected in the study?\",\"answer\":\"BD B10 was chosen from a fragment library using Tanimoto coefficient similarity to trigonelline and tryptamine before testing in cell models.\"},{\"question\":\"What were the key findings of combining BD B10 with gemcitabine?\",\"answer\":\"The combination reduced the gemcitabine dose requirement, enhanced drug efficacy, increased apoptosis, reduced migration, and impeded PI3K/Akt/Nrf2 as well as STAT3 and Wnt/β-catenin signaling.\"}]","Enhancement of gemcitabine toxicity and specificity through PI3K/Akt/Nrf2 pathway inhibition in pancreatic cancer | PDF",1790086289,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b951119cbdbda17cee312d873a946f24.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dd7a5b227e853d8cdf83c4c301e2f456.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3b4eaf5c9db1a4a737f6651bccba5fd4.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/836c984c3cd746d52f602ec5094cc5c9.webp",980,1385]